The Clinical Impact of the Tumor Stroma Ratio in Gastrointestinal Cancer Treatment
The Clinical Impact of the Tumor Stroma Ratio in Gastrointestinal Cancer Treatment
复制标题
DOI：
10.21873/anticanres.16346
复制
发表时间：
2023-04
影响因子：
2
通讯作者：
T. Aoyama;I. Hashimoto;T. Oshima
中科院分区：
文献类型：
--
作者：
T. Aoyama;I. Hashimoto;T. Oshima
胃肠癌的标准治疗方法是手术切除和围手术期的辅助治疗。到目前为止，胃肠道癌症的研究主要集中在癌细胞本身。近年来，肿瘤微环境(TME)已成为研究的热点。TME是一个由多种细胞类型组成的复杂系统，包括肿瘤细胞、内皮细胞、基质细胞、免疫细胞和细胞外成分。其中，肿瘤细胞周围的间质细胞在胃肠道肿瘤中正在被研究。间质细胞在肿瘤的生长、侵袭和转移中起着重要作用。此外，基质细胞与化疗耐药性的增加和化疗投放的减少有关。因此，有必要开发考虑肿瘤-间质相互作用的预后或预测因子。肿瘤间质比率(TSR)最近被证明是一种在各种恶性肿瘤中有前景的预后预测工具。TSR是基于间质与肿瘤面积的比例。最近的研究表明，间质含量高或TSR低与预后不良有关，是各种治疗方式的预测因子。因此，为了优化胃肠道肿瘤的治疗，有必要了解TSR在胃肠道肿瘤中的作用。本文综述了TSR治疗胃肠道肿瘤的背景、现状和前景。
The standard treatment for gastrointestinal cancer is surgical resection and perioperative adjuvant treatment. Thus far, gastrointestinal cancer research has mainly focused on cancer cells themselves. Recently, the tumor microenvironment (TME) has been a subject of investigation. The TME is a complex system composed of various cell types, including tumor cells, endothelial cells, stromal cells, immune cells, and extracellular components. Among them, the stromal cells surrounding tumor cells are being investigated in gastrointestinal cancers. Stromal cells play a role in tumor growth, invasion, and metastasis. Moreover, stromal cells are associated with increased chemotherapy resistance and reduced chemotherapy delivery. Therefore, it is necessary to develop prognostic or predictive factors that consider the tumor-stroma interaction. The tumor stroma ratio (TSR) has recently been shown to be a promising outcome prediction tool in various malignancies. The TSR is based on the proportion of the stroma to tumor area. Recent studies demonstrated that a high amount of stroma or low TSR was associated with a poor prognosis and was a predictor of various treatment modalities. Therefore, to optimize the gastrointestinal cancer treatment, it is necessary to understand the role of the TSR in gastrointestinal cancers. This review summarizes the background, current status, and future perspectives of the TSR for gastrointestinal cancer treatment.